Ying Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying Hu has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
Xingwen Wang
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China
21 shared publicationsShanliang Zheng
School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China
15 shared publicationsKunming Zhao
School of Life Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang Province, China
13 shared publicationsHao Liu
School of Life Science and Technology, Harbin Institute of Technology, Harbin, China
12 shared publicationsQingyu Lin
School of Life Science and Technology, Harbin Institute of Technology, Harbin, China
12 shared publicationsDong Zhao
School of Life Science and Technology, Harbin Institute of Technology, Harbin, China
9 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- p. 1-6
Targeting KRAS condensates to counter therapeutic resistance in colorectal cancer
Increasing lines of evidence suggest that cells achieve biochemical compartmentalization through membrane-bound organelles but also via the dynamic assembly of membrane-less biomolecular condensates to orchestrate complex biological processes1. Liquid–liquid phase separation increases the local concentrations of specific components within defined spatiotemporal contexts, facilitates molecular interactions, and re-organizes signaling dynamics.
- 27 October 2026
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- p. 1-6
Open AccessTargeting KRAS condensates to counter therapeutic resistance in colorectal cancer
Increasing lines of evidence suggest that cells achieve biochemical compartmentalization through membrane-bound organelles but also via the dynamic assembly of membrane-less biomolecular condensates to orchestrate complex biological processes1. Liquid–liquid phase separation increases the local concentrations of specific components within defined spatiotemporal contexts, facilitates molecular interactions, and re-organizes signaling dynamics.
- Open Access
- 16 September 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 3 (1) , 202632
The subcellular landscape of ferroptosis: A cellular organelle perspective
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation. Its execution depends not only on the amount of lipid peroxides, but also on where oxidizable lipids, redox-active iron, reactive oxygen species, and antioxidant defenses are distributed within cells. This review summarizes current evidence for organelle-resolved regulation of ferroptosis and oxidative stress, with emphasis on the endoplasmic reticulum, peroxisomes, mitochondria, lysosomes, lipid droplets, and phase-separated condensates. We discuss how lipid remodeling, ether lipid synthesis, mitochondrial metabolism and local antioxidant defense, ferritinophagy, lysosomal lipid peroxidation, and lipid droplet-mediated fatty acid buffering influence ferroptosis sensitivity. We also summarize how organelle-specific redox defenses and stress-adaptive signaling pathways may shape therapeutic responses. Together, these studies show that ferroptosis is regulated by coordinated changes in lipid metabolism, iron handling, and antioxidant capacity across distinct subcellular compartments.
- 16 September 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 3 (1) , 202632
Open AccessThe subcellular landscape of ferroptosis: A cellular organelle perspective
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation. Its execution depends not only on the amount of lipid peroxides, but also on where oxidizable lipids, redox-active iron, reactive oxygen species, and antioxidant defenses are distributed within cells. This review summarizes current evidence for organelle-resolved regulation of ferroptosis and oxidative stress, with emphasis on the endoplasmic reticulum, peroxisomes, mitochondria, lysosomes, lipid droplets, and phase-separated condensates. We discuss how lipid remodeling, ether lipid synthesis, mitochondrial metabolism and local antioxidant defense, ferritinophagy, lysosomal lipid peroxidation, and lipid droplet-mediated fatty acid buffering influence ferroptosis sensitivity. We also summarize how organelle-specific redox defenses and stress-adaptive signaling pathways may shape therapeutic responses. Together, these studies show that ferroptosis is regulated by coordinated changes in lipid metabolism, iron handling, and antioxidant capacity across distinct subcellular compartments.
- Open Access
- 27 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
LncRNA HITT stabilizes SIRT6 to restrain H3/H4 acetylation and suppress colorectal cancer growth
Histone post-translational modifications are intimately linked to human diseases, including cancers. While diverse regulatory mechanisms have been described, how long non-coding RNAs (lncRNAs) control histone acetylation remains incompletely understood. Here, integrative bioinformatics analysis implicates the lncRNA HITT (HIF-1α inhibitor at the translation level) in histone modification-related pathways. Mechanistically, HITT selectively suppresses H3/H4 acetylation in colorectal cancer cells. Using siRNA-based loss-of-function screening and pharmacological inhibition, we identify the sirtuin deacetylase SIRT6 as an essential mediator of this effect. HITT directly binds SIRT6 and increases SIRT6 protein abundance by attenuating its association with the E3 ubiquitin ligase mouse double minute 2 homolog (MDM2), thereby reducing MDM2-dependent ubiquitination and proteasomal turnover of SIRT6. Conversely, the SIRT6 agonist MDL-800 upregulates the transcription factor E2F1, thereby promoting E2F1-dependent transcription of HITT. Functionally, increased HITT expression cooperates with MDL-800 to inhibit colorectal cancer cell proliferation in vitro and suppress tumor growth in vivo. Collectively, these findings define a feed-forward HITT-SIRT6 axis that stabilizes SIRT6 and constrains histone H3/H4 acetylation homeostasis, highlighting a potential combination strategy for colorectal cancer therapy.
- 27 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessLncRNA HITT stabilizes SIRT6 to restrain H3/H4 acetylation and suppress colorectal cancer growth
Histone post-translational modifications are intimately linked to human diseases, including cancers. While diverse regulatory mechanisms have been described, how long non-coding RNAs (lncRNAs) control histone acetylation remains incompletely understood. Here, integrative bioinformatics analysis implicates the lncRNA HITT (HIF-1α inhibitor at the translation level) in histone modification-related pathways. Mechanistically, HITT selectively suppresses H3/H4 acetylation in colorectal cancer cells. Using siRNA-based loss-of-function screening and pharmacological inhibition, we identify the sirtuin deacetylase SIRT6 as an essential mediator of this effect. HITT directly binds SIRT6 and increases SIRT6 protein abundance by attenuating its association with the E3 ubiquitin ligase mouse double minute 2 homolog (MDM2), thereby reducing MDM2-dependent ubiquitination and proteasomal turnover of SIRT6. Conversely, the SIRT6 agonist MDL-800 upregulates the transcription factor E2F1, thereby promoting E2F1-dependent transcription of HITT. Functionally, increased HITT expression cooperates with MDL-800 to inhibit colorectal cancer cell proliferation in vitro and suppress tumor growth in vivo. Collectively, these findings define a feed-forward HITT-SIRT6 axis that stabilizes SIRT6 and constrains histone H3/H4 acetylation homeostasis, highlighting a potential combination strategy for colorectal cancer therapy.
- 9 July 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (7) , 1047-1063
A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages
Immune checkpoint blockade has achieved remarkable success in cancer treatment; however, enhancing its efficacy remains a challenge. Here we identified an immunoregulatory micropeptide encoded by the long noncoding RNA USP30-AS1 gene, highly expressed in tumor-associated macrophages. The so-designated UEIS (USP30-AS1-encoded immune suppressor) drives macrophages toward a protumorigenic phenotype, thereby inhibiting antitumor T cell immunity. Mechanistically, UEIS is induced in macrophages by cGAS–STING–type I interferon signaling at a relatively late stage following tumoral DNA stimulation, and exerts a negative feedback regulation on the type I interferon signaling by forming biomolecular condensates with TBK1, thereby inhibiting its interaction with STING. Both an intrinsically disordered region and an alpha helix at the extreme N terminus of UEIS were essential for its function. A peptide designed to disrupt UEIS–TBK1 condensation successfully inhibited UEIS function in tumor-associated macrophages, leading to reduced tumor growth and increased response to immune checkpoint blockade. Thus, these findings highlight UEIS as a promising therapeutic target for cancer treatment.
- 9 July 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (7) , 1047-1063
A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages
Immune checkpoint blockade has achieved remarkable success in cancer treatment; however, enhancing its efficacy remains a challenge. Here we identified an immunoregulatory micropeptide encoded by the long noncoding RNA USP30-AS1 gene, highly expressed in tumor-associated macrophages. The so-designated UEIS (USP30-AS1-encoded immune suppressor) drives macrophages toward a protumorigenic phenotype, thereby inhibiting antitumor T cell immunity. Mechanistically, UEIS is induced in macrophages by cGAS–STING–type I interferon signaling at a relatively late stage following tumoral DNA stimulation, and exerts a negative feedback regulation on the type I interferon signaling by forming biomolecular condensates with TBK1, thereby inhibiting its interaction with STING. Both an intrinsically disordered region and an alpha helix at the extreme N terminus of UEIS were essential for its function. A peptide designed to disrupt UEIS–TBK1 condensation successfully inhibited UEIS function in tumor-associated macrophages, leading to reduced tumor growth and increased response to immune checkpoint blockade. Thus, these findings highlight UEIS as a promising therapeutic target for cancer treatment.
- Open Access
- 26 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
LISS enables immune evasion of colorectal cancers irrespective of MSI status
Despite being hailed as a significant advancement in cancer treatment, immune checkpoint blockade (ICB) has not yielded favorable outcomes in colorectal cancer, both in approximately 85% of cases characterized by microsatellite stability (MSS) and approximately 50% of microsatellite instability (MSI) cases. How ICB efficiency in colorectal cancer treatment can be improved remains unclear. Here, we identify a new immunoregulatory long non-coding RNA (lncRNA) gene named lncRNA of IFN-γ-signaling suppressor (LISS). LISS expression is increased in colorectal cancers and is linked to poor prognosis, as well as a high CD8+ score. Functional studies reveal that LISS impairs T cell-mediated cytotoxicity, regardless of MSS/MSI status. Mechanistically, LISS interacts directly with the kinase regulatory domain in calmodulin-dependent kinase (CamK)IIγ through a microdomain containing two independent RNA stem-loops. This interaction prevents the binding and phosphorylation of its substrate signal transducer and activator of transcription1 (STAT1) at serine(S)727, a modification necessary for optimal activation of STAT1 and the subsequent major histocompatibility complex I (MHC-I) gene expression. Analysis of human colorectal cancer samples reveals significant inverse correlations between LISS and pS-STAT1 or MHC-I. The knock-in of LISS in intestinal epithelium promotes adenoma development in Apcmin/+ mice. LISS antisense oligonucleotide (ASO)-based therapies enhance the responses of both MSS and MSI colorectal cancers to ICB in vivo, mainly by restoring MHC-I expression. Therefore, we have identified the previously uncharacterized lncRNA LISS to be a regulator of T cell immunity. Targeting it may be an effective therapeutic strategy to improve ICB in colorectal cancers with varying MSI characteristics.
- 26 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessLISS enables immune evasion of colorectal cancers irrespective of MSI status
Despite being hailed as a significant advancement in cancer treatment, immune checkpoint blockade (ICB) has not yielded favorable outcomes in colorectal cancer, both in approximately 85% of cases characterized by microsatellite stability (MSS) and approximately 50% of microsatellite instability (MSI) cases. How ICB efficiency in colorectal cancer treatment can be improved remains unclear. Here, we identify a new immunoregulatory long non-coding RNA (lncRNA) gene named lncRNA of IFN-γ-signaling suppressor (LISS). LISS expression is increased in colorectal cancers and is linked to poor prognosis, as well as a high CD8+ score. Functional studies reveal that LISS impairs T cell-mediated cytotoxicity, regardless of MSS/MSI status. Mechanistically, LISS interacts directly with the kinase regulatory domain in calmodulin-dependent kinase (CamK)IIγ through a microdomain containing two independent RNA stem-loops. This interaction prevents the binding and phosphorylation of its substrate signal transducer and activator of transcription1 (STAT1) at serine(S)727, a modification necessary for optimal activation of STAT1 and the subsequent major histocompatibility complex I (MHC-I) gene expression. Analysis of human colorectal cancer samples reveals significant inverse correlations between LISS and pS-STAT1 or MHC-I. The knock-in of LISS in intestinal epithelium promotes adenoma development in Apcmin/+ mice. LISS antisense oligonucleotide (ASO)-based therapies enhance the responses of both MSS and MSI colorectal cancers to ICB in vivo, mainly by restoring MHC-I expression. Therefore, we have identified the previously uncharacterized lncRNA LISS to be a regulator of T cell immunity. Targeting it may be an effective therapeutic strategy to improve ICB in colorectal cancers with varying MSI characteristics.
- 8 April 2026
- Published by Elsevier in Developmental Cell
- Vol. 61 (4) , 709-710
Lysosomal rupture: An emerging switch for collective ferroptosis
- 8 April 2026
- Published by Elsevier in Developmental Cell
- Vol. 61 (4) , 709-710
Lysosomal rupture: An emerging switch for collective ferroptosis
- 12 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112240
PKA signaling meets ferroptosis: A new perspertive in cancer treatment
- 12 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112240
PKA signaling meets ferroptosis: A new perspertive in cancer treatment
- Open Access
- 30 August 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (18) , 9695-9728
Hot-spot empowered gold nanoparticles for theranostics in breast cancer
Breast cancer, being the most prevalent malignant tumor among women, confronts severe challenges in its early detection and precise treatment. Traditional diagnostic approaches have drawbacks in terms of sensitivity and specificity, and are invasive, thereby making it arduous to satisfy practical demands. Nanomedicine has introduced novel diagnostic and therapeutic modalities for breast cancer, particularly gold nanoparticles (AuNPs), which have been utilized on account of their distinctive optical and physicochemical attributes. Hot-spot empowered AuNPs have rapidly emerged and demonstrated significant potential in the diagnosis and treatment of breast cancer. From a technical standpoint, the design and synthesis of AuNPs hot-spot are constantly evolving, ranging from the control of number to the control of structure and efficient control of hot-spot utilizations, establishing a development model of “number-structure-efficient utilization”. Hot-spot empowered AuNPs are extensively employed in diagnosis and therapy, facilitating targeted drug delivery, photothermal and photodynamic therapy, and multimodal integration therapy, and also achieving the function of theranostics in an innovative manner. We have deliberated on the challenges and future development prospects of precision medicine for the diagnosis of early breast cancer and individualized treatment.
- 30 August 2025
- Published by Ivyspring International Publisher in Theranostics
- Vol. 15 (18) , 9695-9728
Open AccessHot-spot empowered gold nanoparticles for theranostics in breast cancer
Breast cancer, being the most prevalent malignant tumor among women, confronts severe challenges in its early detection and precise treatment. Traditional diagnostic approaches have drawbacks in terms of sensitivity and specificity, and are invasive, thereby making it arduous to satisfy practical demands. Nanomedicine has introduced novel diagnostic and therapeutic modalities for breast cancer, particularly gold nanoparticles (AuNPs), which have been utilized on account of their distinctive optical and physicochemical attributes. Hot-spot empowered AuNPs have rapidly emerged and demonstrated significant potential in the diagnosis and treatment of breast cancer. From a technical standpoint, the design and synthesis of AuNPs hot-spot are constantly evolving, ranging from the control of number to the control of structure and efficient control of hot-spot utilizations, establishing a development model of “number-structure-efficient utilization”. Hot-spot empowered AuNPs are extensively employed in diagnosis and therapy, facilitating targeted drug delivery, photothermal and photodynamic therapy, and multimodal integration therapy, and also achieving the function of theranostics in an innovative manner. We have deliberated on the challenges and future development prospects of precision medicine for the diagnosis of early breast cancer and individualized treatment.
- 21 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 627, 217815
A previously uncharacterized role of TAp73 in ferroptosis by modulating oxidative homeostasis in cervical cancer
- 21 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 627, 217815
A previously uncharacterized role of TAp73 in ferroptosis by modulating oxidative homeostasis in cervical cancer